Masyuk Tatyana, Masyuk Anatoliy, LaRusso Nicholas
Miles and Shirley Fiterman Center for Digestive Diseases, Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.
Cell Cycle. 2009 May 1;8(9):1324-8. doi: 10.4161/cc.8.9.8253. Epub 2009 May 23.
This review is focused on current findings implicating miRNAs in the polycystic liver diseases, which we categorized as cholangiociliopathies. Our recent data suggest that deregulation of miRNA pathways is emerging as a novel mechanism in the development of cholangiociliopathies. Experimental evidence demonstrates that miRNAs (i.e., miR-15a) influence hepatic cyst growth by affecting the expression of the cell cycle regulator, Cdc25A. Given that abnormalities in many cellular processes (i.e., cell cycle regulation, cell proliferation, cAMP and calcium signaling, the EGF-stimulated mitogen-activated protein kinase (MAPK) pathway and fluid secretion) contribute to the hepatic cystogenesis, the potential role of miRNAs in regulation of these processes is discussed.
本综述聚焦于当前涉及微小RNA（miRNA）在多囊肝病中的研究发现，我们将多囊肝病归类为胆管纤毛病。我们最近的数据表明，miRNA通路失调正成为胆管纤毛病发生发展的一种新机制。实验证据表明，miRNA（如miR-15a）通过影响细胞周期调节因子Cdc25A的表达来影响肝囊肿生长。鉴于许多细胞过程（如细胞周期调节、细胞增殖、环磷酸腺苷（cAMP）和钙信号传导、表皮生长因子（EGF）刺激的丝裂原活化蛋白激酶（MAPK）通路以及液体分泌）的异常都与肝囊肿形成有关，本文讨论了miRNA在调节这些过程中的潜在作用。
